In this high-risk population of children, taking nebulized ICS (budesonide inhalation suspension) after a hospitalization or ED visit for asthma was associated with a reduced risk of a repeat ...

In the phase 3b BATURA trial, Airsupra—a pressurized metered-dose inhaler containing albuterol and budesonide—significantly ...

AstraZeneca's inhaled rescue medication, Airsupra (albuterol/budesonide), has shown significant efficacy in reducing the risk ...

Topline results were announced from a trial evaluating albuterol/budesonide inhaler in patients with intermittent or mild persistent asthma.

AstraZeneca has announced promising results from the BATURA Phase IIIb trial, showcasing the effectiveness of AIRSUPRA ...

UK-based pharmaceutical company AstraZeneca has reported that its Phase IIIb BATURA trial of Airsupra (albuterol/budesonide) ...

The BATURA trial ended early due to high efficacy data at pre-planned analysis. Topline results were announced from a phase 3b trial evaluating albuterol/budesonide metered dose inhaler in ...

The phase 3b BATURA study showed Airsupra (albuterol/budesonide) achieved a statistically significant reduction in the risk of severe asthma exacerbations when used as needed for rescue therapy ...

AstraZeneca's Airsupra (albuterol/budesonide) met the primary endpoint in the Phase III BATURA trial, significantly reducing ...

AstraZeneca’s inhaled rescue medication, Airsupra (albuterol/budesonide), has shown significant efficacy in reducing the risk of severe asthma exacerbations in patients with intermittent or mild ...